September 2015 - Cancer Currents Blog
- "Fine Tuning" Engineered T Cells May Extend Immunotherapy Approach to More Cancer Types
Engineering immune cells to have a decreased affinity for their targets on cancer cells may not weaken their efficacy but may reduce the risk of side effects.
- Cancer Trends: Influencing Care and Research Priorities
Many of the trends being seen in cancer are changing how we view cancer and how we address it, from prompting research to identify the underlying causes of cancers increasing in incidence to informing research on treatment and prevention.
- CPTAC, the Complementary Sibling of TCGA: An Interview with Dr. Henry Rodriguez about NCI’s Proteomics Program
Dr. Henry Rodriguez explains the goals and future directions of CPTAC, a collaborative consortium of institutions and investigators who study cancer proteomics.
- For Some Children with Cancer, Genomic Information May Help Guide Treatment Decisions
Genomic methods, such as DNA sequencing, may help doctors manage the treatment of children and young adults with cancer.
- FDA Approves Rolapitant to Prevent Nausea and Vomiting from Chemotherapy
The FDA has approved rolapitant to prevent chemotherapy-induced nausea and vomiting.
- NCI Initiative to Speed Development of Childhood Cancer Therapies
NCI has awarded grants to five research teams to participate in its Pediatric Preclinical Testing Consortium, which is intended to help to prioritize which agents to pursue in pediatric clinical trials.
- Intraperitoneal Chemotherapy in Advanced Ovarian Cancer Improves Survival, But Is Underused
Use of intraperitoneal chemotherapy, along with intravenous chemotherapy, improves survival in some women with advanced ovarian cancer, but its use in clinical practice has been limited, according to a new study.
- FDA Approves Sonidegib for Some Patients with Advanced Basal Cell Carcinoma
The FDA has approved sonidegib for the treatment of patients with locally advanced basal cell carcinoma.